Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Fuller, M. A. Articles by Durkin, M. B. Search for Related Content PubMed Citation Articles by Fuller, M. A. Articles by Durkin, M. B. Costs, Cost Analysis Service Utilization Atypical Neuroleptics

Service Use and Costs Among VA Patients With Schizophrenia Taking Risperidone or Olanzapine

OBJECTIVE: The authors compared the changes in health care utilization and costs between a group of patients with schizophrenia who started treatment with risperidone and a group that started treatment with olanzapine. METHODS: A retrospective analysis was conducted of patients with schizophrenia who were given an initial prescription for risperidone or for olanzapine between March 1997 and March 1999. The change in utilization and cost of inpatient hospitalizations, outpatient clinic visits, medications, and total health care services from one year before to one year after initiation of treatment for the two groups was compared. RESULTS: The risperidone and olanzapine groups comprised 325 and 285 patients, respectively. Total health care costs declined by $1,536 on average for patients in the risperidone group and increased by $4,217 on average for patients in the olanzapine group after initiation of treatment. The difference was statistically significant, and it was largely due to drug and hospitalization costs. Drug costs for patients in the risperidone group underwent a smaller increase than those for patients in the olanzapine group ($991 versus $1,861). Hospitalization costs decreased by $4,011 for patients in the risperidone group and increased by $1,423 for those in the olanzapine group. CONCLUSIONS: Total health care costs declined for patients taking risperidone and increased for patients taking olanzapine after treatment was initiated.

This article has been cited by other articles:

				T. A. Hardy, A. L. Meyers, J. Yu, S. S. Shankar, H. O. Steinberg, and N. K. Porksen Acute Insulin Response and {beta}-Cell Compensation in Normal Subjects Treated With Olanzapine or Risperidone for 2 Weeks: Response to Jindal Diabetes Care, July 1, 2007; 30(7): e70 - e70. [Full Text] [PDF]

				P. A. Russo, M. W. Smith, and M. Namjoshi Health care costs for schizophrenia patients started on olanzapine versus risperidone Am. J. Health Syst. Pharm., March 15, 2005; 62(6): 610 - 615. [Abstract] [Full Text] [PDF]

				G. G Liu, S. X Sun, D. B Christensen, and X. Luo Cost Comparisons of Olanzapine and Risperidone in Treating Schizophrenia Ann. Pharmacother., January 1, 2004; 38(1): 134 - 141. [Abstract] [Full Text] [PDF]

				M. W. Smith and P. G. Barnett Direct Measurement of Health Care Costs Med Care Res Rev, September 1, 2003; 60(3_suppl): 74S - 91S. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us